Samsung Bioepis turns to China to accelerate biotech innovation
Samsung Bioepis is moving to deepen its global research footprint, signing a partnership with a major Chinese biotech platform to scout and develop next-generation therapies. The biopharmaceutical company that develops, manufactures and commercializes high-quality biosimilars — lower-cost, clinically proven alternatives to expensive biologic medicines — said Wednesday it signed a memorandum of understanding with ATLATL Innovation Center, a biotech incubation platform, to expand its open innovation strategy and collaborate with emerging biotech firms. Under the agreement, Samsung Bioepis will identify promising startups and support their early-stage growth by providing access to ATLATL’s research facilities and infrastructure. The partnership marks the company’s first collaboration with an overseas open innovation institution. ATLATL Innovation Center operates shared laboratories, office space and contract research organization services across key biotech clusters, including Beijing, Shanghai, Singapore and Australia. The platform connects venture companies with global partners t
